Rapalogs are a class of drugs that are derived from rapamycin, a naturally occurring compound. They function by inhibiting a protein called mammalian target of rapamycin (mTOR), which is involved in regulating cell growth and division. By blocking mTOR, rapalogs can interfere with cellular signaling pathways that promote cell proliferation (growth and division), angiogenesis (the formation of new blood vessels), and immune response. These drugs have been extensively studied in the field of cancer treatment, as unchecked cell growth is a hallmark of cancer. Rapalogs have also shown potential in the management of various other conditions, including autoimmune disorders, organ transplant rejection, and certain types of rare genetic diseases. Their precise mechanism of action and therapeutic applications continue to be investigated, making rapalogs an area of active research in the medical field.